Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
They're the most important executive at most small developmental or early commercialization concerns.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Let's check out the latest charts and indicators.
But this off-patent tie-up comes with some questions -- such as why are so many Mylan executives hanging on?
What new management means for Mylan shareholders moving forward.
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.